Forskning ved Københavns Universitet - Københavns Universitet

Forside

A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • Selidji Todagbe Agnandji
  • Bertrand Lell
  • José Francisco Fernandes
  • Béatrice Peggy Abossolo
  • Barbara Gaelle Nfono Ondo Methogo
  • Anita Lumeka Kabwende
  • Ayola Akim Adegnika
  • Benjamin Mordmüller
  • Saadou Issifou
  • Peter Gottfried Kremsner
  • Jahit Sacarlal
  • Pedro Aide
  • Miguel Lanaspa
  • John J Aponte
  • Sonia Machevo
  • Sozinho Acacio
  • Helder Bulo
  • Betuel Sigauque
  • Eusébio Macete
  • Pedro Alonso
  • Salim Abdulla
  • Nahya Salim
  • Rose Minja
  • Maxmillian Mpina
  • Saumu Ahmed
  • Ali Mohammed Ali
  • Ali Takadir Mtoro
  • Ali Said Hamad
  • Paul Mutani
  • Marcel Tanner
  • Halidou Tinto
  • Umberto D'Alessandro
  • Hermann Sorgho
  • Innocent Valea
  • Biébo Bihoun
  • Issa Guiraud
  • Berenger Kaboré
  • Olivier Sombié
  • Robert Tinga Guiguemdé
  • Jean Bosco Ouédraogo
  • Mary J Hamel
  • Simon Kariuki
  • Martina Oneko
  • Chris Odero
  • Kephas Otieno
  • Norbert Awino
  • Meredith McMorrow
  • Vincent Muturi-Kioi
  • John Lusingu
  • Theander, Thor Grundtvig
  • RTS,S Clinical Trials Partnership
The candidate malaria vaccine RTS,S/AS01 reduced episodes of both clinical and severe malaria in children 5 to 17 months of age by approximately 50% in an ongoing phase 3 trial. We studied infants 6 to 12 weeks of age recruited for the same trial.
OriginalsprogEngelsk
TidsskriftNew England Journal of Medicine
Vol/bind367
Udgave nummer24
Sider (fra-til)2284-95
Antal sider12
ISSN0028-4793
DOI
StatusUdgivet - 2012

ID: 43233798